[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100494919":3},{"organization":4,"outcomesModule":7,"designInfo":38,"detailedDescription":47,"studyPopulation":37,"armGroups":48,"interventions":60,"overallOfficials":69,"centralContacts":74,"locations":84,"responsibleParty":202,"collaborators":205,"id":209,"slug":210,"hasResults":211,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":215,"eligibilityCriteria":216,"healthyVolunteers":211,"sex":217,"minAge":218,"maxAge":37,"enrollmentInfo":219,"targetDuration":37,"studyType":222,"phases":223,"briefSummary":225,"conditions":226,"keywords":228,"overallStatus":87,"whyStopped":37,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":241},{"fullName":5,"class":6},"Population Health Research Institute","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":25,"otherOutcomes":37},[9,13,17,21],{"measure":10,"description":11,"timeFrame":12},"Primary \"Hierarchical\" Composite Outcome of (Part 1):","Target dose of beta blockers (BB), angiotensin receptor-neprilysin inhibitor (ARNI) or angiotensin-converting enzyme inhibitor (ACEi) \u002F angiotensin receptor blocker (ARB), mineralocorticoid receptor antagonist (MRA), and sodium-glucose cotransporter-2 inhibitor (SGLT2i) at 90 days.","30 and 90 days",{"measure":14,"description":15,"timeFrame":16},"Primary \"Hierarchical\" Composite Outcome of (Part 2):","2\\. Guideline-directed medical therapy (GDMT) intensification at 30 days, defined as:\n\n1. initiation or up-titration of a beta blocker;\n2. switch from another beta blocker to carvedilol, bisoprolol, or extended-release metoprolol succinate;\n3. initiation or up-titration of an angiotensin-converting enzyme inhibitor (ACE inhibitor), angiotensin receptor blocker (ARB), or angiotensin receptor-neprilysin inhibitor (ARNI);\n4. switch from an angiotensin-converting enzyme inhibitor (ACE inhibitor) or angiotensin receptor blocker (ARB) to an angiotensin receptor-neprilysin inhibitor (ARNI);\n5. initiation or up-titration of a mineralocorticoid receptor antagonist (MRA); or\n6. initiation of a sodium-glucose cotransporter-2 inhibitor (SGLT2 inhibitor).","Time Frame: 30 and 90 Days",{"measure":18,"description":19,"timeFrame":20},"Primary \"Hierarchical\" Composite Outcome of (Part 3):","Change in health status, as measured by the Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) summary score at 90 days.","Time Frame: 30 and 90 days.",{"measure":22,"description":23,"timeFrame":24},"Co-primary \"Hierarchical\" Composite Outcome of:","1. All-cause death at 180 days.\n2. Heart failure (HF) hospitalization at 180 days.\n3. All-cause emergency department (ED) visit at 180 days.\n4. Change in Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) summary score at 90 days.\n\nThese Co-Primary Hierarchical Composite Outcomes were the original Primary Outcomes for this trial. The Primary \"Original\" Outcome listed below applies only to the single-center pilot phase of the trial.","90 and 180 days",[26,30,34],{"measure":27,"description":28,"timeFrame":29},"Guideline-Directed Medical Therapy (GDMT) use","Achievement of at least 50% of the target doses of beta blockers, angiotensin-converting enzyme inhibitors\u002Fangiotensin receptor blockers or angiotensin receptor-neprilysin inhibitors, mineralocorticoid receptor antagonists, sodium-glucose cotransporter-2 inhibitors at 90 days.","90 days",{"measure":31,"description":32,"timeFrame":33},"Clinical Outcomes","i) Time to composite all-cause death, heart failure hospitalization, or all-cause emergency department visit at 180 days ii) Components of composite endpoint\n\n* Time to all-cause death\n* Time to heart failure hospitalization\n* Time to all-cause emergency department visit iii) Change in health status (Kansas City Cardiomyopathy Questionnaire-12 summary score) at 90 days\n\nThe Secondary \"Original\" Outcomes listed below apply only to the single-center pilot phase.","90 days and 180 days",{"measure":35,"description":36,"timeFrame":33},"Healthcare utilization","i) direct healthcare cost at 90 and 180 days. ii) number of virtual and in-person clinic visits per patient in 90 days.",null,{"allocation":39,"interventionModel":40,"interventionModelDescription":41,"primaryPurpose":42,"observationalModel":37,"timePerspective":37,"maskingInfo":43},"RANDOMIZED","PARALLEL","This is an unblinded parallel multi-center Randomized Controlled Trial (RCT) of virtual HF clinics + routine care versus routine care alone in patients discharged after a hospitalization or urgent\u002Femergency visit for HF. Randomization will be at the level of the patients and stratified by hospital site.\n\nPatients and clinicians will be unblinded, but those analyzing data will be blinded. We will adopt a pragmatic approach to this study.","HEALTH_SERVICES_RESEARCH",{"masking":44,"maskingDescription":37,"whoMasked":45},"SINGLE",[46],"OUTCOMES_ASSESSOR","Heart failure (HF) is a leading cause of mortality and morbidity across the world. Access to specialized HF clinics remains limited despite evidence that multidisciplinary HF care improves outcomes. VICTORY-HF is an international, multicentre, pragmatic randomized controlled trial evaluating whether a virtual HF clinic, in addition to routine care, improves implementation and clinical outcomes among patients recently discharged following hospitalization or urgent care visits for HF.\n\nParticipants will be randomized to a 90-day virtual HF clinic plus routine care or routine care alone. The virtual clinic will provide structured remote follow-up, monitoring, and optimization of guideline-directed medical therapy (GDMT). The trial will evaluate the effect of the intervention on the medication optimization, patient-reported health status (KCCQ-12), all-cause mortality, HF hospitalization, and emergency department visits.\n\nThe multi-centre randomized trial (CTO Project ID 4277) was preceded by a pilot randomized controlled trial (HiREB Project ID 5441) to assess the feasibility and acceptability of the intervention, refine virtual care processes, and inform the final trial protocol. Data collected during the pilot phase were limited to feasibility and process outcomes, distinct from the objectives and outcomes of the multi-center randomized controlled trial.",[49,55],{"label":50,"type":51,"description":52,"interventionNames":53},"Virtual HF care","EXPERIMENTAL","Patients will receive virtual HF care to optimize medical therapies",[54],"Other: Virtual HF Care",{"label":56,"type":6,"description":57,"interventionNames":58},"Routine HF care","Participants will receive routine HF care",[59],"Other: Routine HF Care",[61,65],{"type":6,"name":62,"description":63,"armGroupLabels":64,"otherNames":37},"Virtual HF Care","Patients will receive virtual visits for 3 months following hospitalization \u002F emergency department (ED) visit for HF. Physiologic measures will be monitored remotely and therapies will be optimized.",[50],{"type":6,"name":66,"description":67,"armGroupLabels":68,"otherNames":37},"Routine HF Care","Care as determined by the treating physician",[56],[70],{"name":71,"affiliation":72,"role":73},"Harriette Van Spall, MD","McMaster University","PRINCIPAL_INVESTIGATOR",[75,81],{"name":76,"role":77,"phone":78,"phoneExt":79,"email":80},"Harriette GC Van Spall, MD MPH","CONTACT","(905) 521-2100","40601","Harriette.VanSpall@phri.ca",{"name":82,"role":77,"phone":37,"phoneExt":37,"email":83},"VICTORY-HF Project office","victory-hf@phri.ca",[85,102,112,121,135,148,163,176,189],{"facility":86,"status":87,"city":88,"state":89,"zip":90,"country":91,"countryCode":92,"cosmosGeoPoint":93,"geoPoint":98,"contacts":99},"St. Joseph's Healthcare Hamilton","RECRUITING","Hamilton","Onatrio","L8N 4A6","Canada","CA",{"type":94,"coordinates":95},"Point",[96,97],-79.84963,43.25011,{"lat":97,"lon":96},[100],{"name":101,"role":77,"phone":37,"phoneExt":37,"email":37},"Katie Connolly, Dr",{"facility":103,"status":87,"city":88,"state":104,"zip":105,"country":91,"countryCode":92,"cosmosGeoPoint":106,"geoPoint":108,"contacts":109},"Hamilton General Hospital","Ontario","L8L 2X2",{"type":94,"coordinates":107},[96,97],{"lat":97,"lon":96},[110],{"name":111,"role":77,"phone":37,"phoneExt":37,"email":37},"Harriette Van Spall, Dr",{"facility":113,"status":87,"city":88,"state":104,"zip":114,"country":91,"countryCode":92,"cosmosGeoPoint":115,"geoPoint":117,"contacts":118},"Juravinski Hospital Cancer Centre","L8V 5C2",{"type":94,"coordinates":116},[96,97],{"lat":97,"lon":96},[119],{"name":120,"role":77,"phone":37,"phoneExt":37,"email":37},"Serena Gundy, Dr.",{"facility":122,"status":123,"city":124,"state":104,"zip":37,"country":91,"countryCode":92,"cosmosGeoPoint":125,"geoPoint":129,"contacts":130},"Thunder Bay Regional Health Sciences Centre","NOT_YET_RECRUITING","Thunder Bay",{"type":94,"coordinates":126},[127,128],-89.25018,48.38202,{"lat":128,"lon":127},[131],{"name":132,"role":77,"phone":133,"phoneExt":37,"email":134},"Vahid Akbari","807-684-7580","Vahid.Akbari@tbh.net",{"facility":136,"status":87,"city":137,"state":104,"zip":37,"country":91,"countryCode":92,"cosmosGeoPoint":138,"geoPoint":142,"contacts":143},"Unity Health Toronto","Toronto",{"type":94,"coordinates":139},[140,141],-79.39864,43.70643,{"lat":141,"lon":140},[144],{"name":145,"role":77,"phone":146,"phoneExt":37,"email":147},"Peter Mitoff","416-766-1162","Peter.Mitoff@unityhealth.to",{"facility":149,"status":87,"city":150,"state":37,"zip":37,"country":151,"countryCode":152,"cosmosGeoPoint":153,"geoPoint":157,"contacts":158},"Fattouma Bourguiba Hospital","Monastir","Tunisia","TN",{"type":94,"coordinates":154},[155,156],10.82617,35.77799,{"lat":156,"lon":155},[159],{"name":160,"role":77,"phone":161,"phoneExt":37,"email":162},"Semir Nouira","+21673106000","semir.nouira@rns.tn",{"facility":164,"status":87,"city":165,"state":37,"zip":37,"country":151,"countryCode":152,"cosmosGeoPoint":166,"geoPoint":170,"contacts":171},"Hedi Chaker Hospital","Sfax",{"type":94,"coordinates":167},[168,169],10.76028,34.74056,{"lat":169,"lon":168},[172],{"name":173,"role":77,"phone":174,"phoneExt":37,"email":175},"Leila Abid","+21674244511","leilaabidt@yahoo.fr",{"facility":177,"status":87,"city":178,"state":37,"zip":37,"country":151,"countryCode":152,"cosmosGeoPoint":179,"geoPoint":183,"contacts":184},"Sahloul Hospital","Sousse",{"type":94,"coordinates":180},[181,182],10.63699,35.82539,{"lat":182,"lon":181},[185],{"name":186,"role":77,"phone":187,"phoneExt":37,"email":188},"Riadh Boukef","+21673369411","riadboukef@gmail.com",{"facility":190,"status":87,"city":191,"state":37,"zip":37,"country":151,"countryCode":152,"cosmosGeoPoint":192,"geoPoint":196,"contacts":197},"Military Hospital","Tunis",{"type":94,"coordinates":193},[194,195],10.16579,36.81897,{"lat":195,"lon":194},[198],{"name":199,"role":77,"phone":200,"phoneExt":37,"email":201},"Wafa Fehri","+21671391133","wafafehri@gmail.com",{"type":73,"investigatorFullName":203,"investigatorTitle":204,"investigatorAffiliation":5,"oldNameTitle":37,"oldOrganization":37},"Harriette Van Spall","Assistant Professor of Medicine, Division of Cardiology, McMaster University, Population Health Research Institute",[206,208],{"name":207,"class":6},"Hamilton Health Sciences Corporation",{"name":72,"class":6},"100494919","virtual-care-to-improve-outcomes-and-recovery-from-heart-failure-hospitalization-100494919",false,"NCT05724433","VIrtual Care To Improve Outcomes and RecoverY From Heart Failure Hospitalization","VIrtual Care To Improve Outcomes and RecoverY From Heart Failure Hospitalization (VICTORY-HF) RCT","VICTORY-HF","Inclusion Criteria:\n\nAdult patients ≥ 18 years old who:\n\n1. Are being discharged after hospitalization or urgent visit for HF as\n\n   1. a primary diagnosis or\n   2. significant complication (prolonging length of stay) of another diagnosis OR Have been referred for an initial consult at a cardiology clinic within 1 week of hospitalization or urgent visit for HF as a primary or secondary diagnosis, as described above.\n2. Have left ventricular ejection fraction (LVEF) \\\u003C 50% within the preceding 3 months.\n3. Have NT-proBNP of \\> 900 pg\u002Fml during hospital admission or within 7 days after discharge from the ED\n4. Have a mailing address for patient or caregiver\n5. Provide verbal consent\n\nExclusion Criteria:\n\n1. Died or left hospital before medically advised hospital discharge\n2. Unable to self-assess or communicate symptoms (e.g. clinically evident dementia)\n3. Unable to engage with digital health technology or follow up\n4. Severe valve disease\n5. Recipient of or on waiting list for LVAD or cardiac transplant\n6. Complex congenital heart disease, hypertrophic obstructive cardiomyopathy, or amyloid cardiomyopathy\n7. Severe lung disease with symptoms on minimal exertion, forced expiratory volume during 1 second (FEV1) \\\u003C 1 litre, severe pulmonary hypertension with RVSP \\> 60 mm Hg, or on home oxygen\n8. Severe kidney disease (persistent eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m2)\n9. Active malignancy\n10. Receiving palliative care or expected life expectancy \\\u003C 6 months","ALL","18 Years",{"count":220,"type":221},891,"ESTIMATED","INTERVENTIONAL",[224],"NA","The clinic visits (intervention) will continue for 90 days, which represents the follow-up period for the primary medication and health status outcomes. The co-primary clinical outcomes will be obtained at 180 days.",[227],"Heart Failure",[227,229,230,231],"Randomized Controlled Trial","Digital Health","Knowledge Translation","2026-08-04",{"date":234,"type":235},"2026-08-07","ACTUAL",{"date":237,"type":235},"2023-01-23",{"date":239,"type":221},"2026-12-31",{"name":5,"class":6},9]